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Abstract  In this report, we investigated CpG density 
occurred in promoter regions (PRs) and downstream 
flanking regions (DFR) of 61 human protein kinase 
oncogenes (PKOs), together with other three species: 
chimpanzee, mouse and horse. The quantified numbers of 
CpGs in the PRs of human PKOs were much higher than 
those of chimpanzee, mouse and horse, suggesting that the 
CpG density changes among the four species are associated 
with species evolution. Human PKOs with relatively high 
number of CpGs in the PRs showed stronger gene expression 
than the mouse PKOs in tumour tissues, but not in normal 
tissues. Furthermore, human PKOs with extremely high 
density of CpGs in the PRs exhibited much lower expression 
in tumour tissues than in normal tissues. Our data initially 
suggest that the occurrence and density of CpGs in the PRs 
of PKOs play an important role in regulating gene expression 
associated with the tumorigenesis. Thus, further 
improvement of our understanding of the density and spatial 
arrangement of CpGs in the PRs of PKOs and other 
oncogenes involved in tumorigenesis is very important for 
providing preventive and therapeutic strategies for human 
cancer. 
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1. Introduction 
Presence of high CpGs density on the gene promoter 
region (PR) is believed to be associated with high gene 
expression [1-3]. This PR with high CpG density stretches 
from 0.5 to 2 kilo base pairs (kbp) upstream of gene 
translation start sites (TSS) [4-6]. Within the region when a 
section longer than 200bp is characterised by presence of  
70% G+C dinucleotides, then this section is often referred to 
as a CpG Island [7]. The CpG Islands (CGIs) are found in 
two-third of house-keeping genes and a quarter of 
tissue-specific genes, respectively [8].  
What makes the presence of CpG dinucleotides in the 
CGIs significant is the fact that the cytosines in a CGI are not 
often methylated. High CpG density make the whole CGI 
serves as a ‘Passover’ sign during the de novo methylation of 
blastocyst genome by DNA cytosine methyltransferases 
(Dnmt3a and Dnmt3b) [9]. Thus, any mutation, which adds 
cytosines into the CGI, is more likely to increase the density 
of CpGs in the gene PRs. While mismatches of dinucleotides 
in young cells are repaired quickly, the ageing cells do not or 
never correct their genomic errors. This is because of that 
majority of genes involved in the DNA repair and 
methyltransferases (Dmnt1) are rarely transcribed in 
senescent cells [10-12]. Consequently these genomic 
changes are passed down from generation to generation, 
which contribute to high CpG density in the gene PRs. The 
high CpG density causes high gene expressions reminiscent 
of cancer genes. It has been shown that CpG island 
methylation in the PRs is likely to be an important 
mechanism in modulating gene expression in several cancers 
[13, 14]. In addition, an apparent drop of CpGs in the PR 
causes inactivation of tumour suppressor genes, aberrant 
cellular pathways such as DNA repair, cell cycle, apoptosis 
and cell division and imprinted genetic disorder [15-18].  
Oncogenesis is related to various processes including the 
accumulation of deoxyribonucleic acid (DNA) nucleotides 
changes on the precancerous cell genome. The mechanisms 
by which the nucleotides (genetic/epigenetics) changes 
cause cancer have been proposed in proto-oncogenes, 
tumour suppressor and stability genes. However, the 
relationship between unusual variation of CpG dinucleotides 
in the human protein kinase genes PRs remains to be deeply 
investigated. The aim of this study is to investigate whether 
occurrence and density of CpG in the PRs of protein kinase 
oncogene (PKO) contributes to human oncogenesis. The 
research quantified the number of CpG dinucleotides in the 
1K base pairs upstream of TSS and downstream flanking 
region of 61 PKOs in four mammalian species. The 
information acquired from this study has a potential for a 
30 Cross-species Comparison of CpG Density in the Promoter Regions of Protein Kinase Oncogenes  
 
better understanding of oncogenesis in human.  
2. Material and Method 
2.1. Screening the Protein Kinase Oncogenes from the 
Human Kinome 
The protein kinase oncogenes (PKOs) used in this study 
was screened out from the 518 protein kinase (PK) genes of 
the human kinome, which was published by Manning and 
colleagues [19]. Each of the 518 PK genes was then searched 
for in the Online Mendelian Inheritance in Man database 
(OMIM) at the National Centre for Biotechnology 
Information (NCBI) website, 
(http://www.ncbi.nlm.nih.gov/). The information retrieved 
from the database revealed full description of the gene, its 
functions (oncogenic or not) and peer reviewed journal 
articles which confirmed pro-oncogenic potential of the gene. 
Based on this information, a decision is made to either 
include or exclude it from the list of possible PKOs that 
would be investigated. The same process was repeated for 
the whole of 518 PK genes. This list of thoroughly screened 
PKOs from human, acted as a template for downloading the 
DNA sequences of orthologous PKOs from the mouse, horse 
and chimpanzee. 
2.2. Obtaining DNA Sequences from the Ensembl 
Database 
The DNA sequences of human PKOs were searched from 
Ensembl release 54 (GRCh37, 
http://www.ensembl.org/Homo_sapiens/Info/Index) where 
61 human PKOs were selected for intensive analysis and 
cross-species comparison.  
The retrieved data contained gene markers and the real 
gene links from different assemblies, in order to obtain the 
accurate gene sequences. To determine the accurate position 
of the TSS, each downloaded DNA sequence was carefully 
compared with the alignment of the same gene from 
Evidence Viewer (EV) and Sequence Viewer (SV) of NCBI 
website. The down-stream section of the PR (10–25 bases 
immediately upstream from the TSS) was aligned back with 
the corresponding section of the same gene illustrated on the 
EV and SV. Complete alignment confirmed correctness of 
the downloaded gene-including DNA sequence.  
Each gene-including DNA sequence downloaded includes 
5K bases (bs) upstream from the transcription start site (TSS), 
the full length of the gene (extron+intron) and the 1K bs 
downstream from the 3’ end of the gene (stop codon). If the 
inter-gene distance (the distance between the TSS of the 
gene being downloaded and the 3’ end of the upstream gene) 
is less than 5K bs, then the downloaded DNA sequence 
includes the full sequence within the inter-gene distance, the 
full length of the gene and 1K bs downstream from the 3’ end 
of the gene. In each gene-including DNA sequence, the 
sequence upstream of the TSS is termed as a putative PR and 
the sequence downstream of the 3’ end of the gene is the 
downstream flanking region (DFR [20, 21]. 
The sequences of 1K bs at either end of the gene were 
selected for counting the density of CpGs. The gene 
sequence key elements such as: (1) 15 bs from the start 
codon (ATG) and the stop codon; (2) 1K bs from either 
flanking region of the transcript; (3) gene descriptions; (4) 
location of the gene either on plus (+1) or minus (-1) strand; 
(5) the number of exons; (6) location of the gene on the 
chromosome; (7) the coordinate of each exon and intron, 
were fed into the Matlab program for analysis. The same 
process was repeated for the 61 PKOs in the human, mouse, 
horse and chimpanzee. The analysed results were stored in 
both Matlab and excel tab-limited formats for convenient 
access.  
2.3. Downloading Gene Expression Data 
In order to investigate whether the CpG density at the 1k 
bp upstream of TSS was related to high expression level or 
not, twenty (20) PKOs with promoter region (PR) CpG 
densities that range from 1-138 were selected. The 
expression data of these PK oncogenes were downloaded 
from the GeneHub-GEPIS website. Gene expression data 
were retrieved in 34 normal and tumour tissues/organs from 
human and mouse. The gene expression data of the PKOs 
from both normal and tumour tissues were derived from the 
human and mouse (the data from other two species are 
unavailable currently) expressed sequence tag (EST). These 
data were used to compare the quantitative relationship 
between the expression levels of PKOs and the CpG density 
in their PRs.  
2.4. How Gene Expression Data Are Determined From 
GeneHub-GEPIS Database 
The algorithms used to calculate gene expression profile 
were previously described by Zhang and colleagues [22]. 
These expression data were integrated into human and 
mouse genes databases by GeneHub, a component of 
GeneHub-GEPIS database. The merged databases (GEPIS 
and GeneHub) incorporated gene specificity and biological 
characteristics relevant to the expression data which has 
made these data suitable for this research [22]. 
3. Results 
3.1. CpG Density at the Promoter Region (PR) of Protein 
Kinase Oncogenes 
The study screened out 61 protein kinase oncogenes from 
the human kinome, which were used as template to 
download the homologous genomic sequences from 
chimpanzee, mouse and horse. The DNA sequences of these 
species were fed into self-written program for analysis. The 
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CpG island is a DNA sequence equal or longer than the 
starting window (SW), in which the observed/expected (O/E) 
value of CpGs should be equal or higher than 0.6 and 
G%+C%>50 [23]. The method used for CpG island 
identification was according to a previous report [18, 20] 
with some modifications. A SW of 200 bs was applied from 
the 5’ end of the DNA sequence, with the G%+C% and O/E 
value of the CpGs being calculated within the SW while the 
SW was moving step-by-step towards the TSS. To avoid the 
mathematical CpG island, 7 CpGs/200 bs was selected as a 
reasonable cutoff for a CpG island identified in the SW [23]. 
Two individual CpG islands were connected if they were 
separated by less than 50 bs. The CpG island information 
that included the number of CpGs in each CpG island, the 
density of the CpG island (number of CpG/100 bs), the 
position of each CpG within the CpG island, the starting and 
ending coordinates of the CpG island along the gene 
sequence were collected for statistical analysis using 
two-way ANOVA. 
3.1.1. Human 
Figure 1 shows the CpG density and distribution in both 
PRs and DFRs of 61 human PKOs. On an average, 61 human 
PKOs had a number of 51.5 CpGs in their PRs and 15.8 in 
their DFRs, respectively. Forty-six PKOs (75.4%) showed 
very high CpG density with over 20 CpGs identified in their 
PRs while fifteen PKOs (24.6%) had a low CpG density with 
the CpGs less than 20 (Figure 1). Five PKOs: HIPK2, IGF1R, 
PKCE, CAMK1B and PIM1 showed the highest density of 
CpGs in their PRs, with a number of 139, 134, 119, 116 and 
103 CpGs quantified while they had a number of 40, 13, 20, 
18 and 23 CpGs identified in their DFRs. Three PKOs had a 
very low density of CpGs in their PRs, with MER only 
containing 1, FRK and TRKA having 10 each while they 
also had 10, 5 and 8 CpGs quantified in their DFRs (Fig 1). 
 
Figure 1.  Human PK oncogene CpG density at the promoter regions (PRs) and downstream flanking regions (DFRs). The CpG density clusters (see closed 
brace on the right hand side) are labelled as high and low CpG Density (CGD). Low CGD means less than 20 dinucleotides on 1kbp upstream of TSS; High 
CGD is greater than 20 dinucleotides on 1kbp upstream of TSS. Each of the dark and blue vertical spikes represents a pair of CpG dinucleotides and 
horizontal line represents the length of 1kb of the PR and DFR respectively. PK genes are plotted in a descending order of the CpG density in their PRs. The 
number in bracket next to the low or high CGD represents the number of genes in that cluster. The result shows 75% of the human PKOs have high CGD and 
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3.1.2. Chimpanzee 
Figure 2 shows the CpG density and distribution in both PRs and DFRs of 61 chimpanzee PKOs. The average number of 
CpGs in the PRs and DFRs of the 61 chimpanzee PKOs were 44.7 and 14.6, respectively. Among the 61 PKOs, 42 (68.9%) 
had a high CpG density while 31.1% had a low CpG density in their PRs. Only two Chimpanzee PKOs showed to have more 
than 100 CpGs in their PRs, with SGK1 having 121 and BRK 104 (Fig 2). Both genes had a low density of CpGs in their 
DFRs too, with 8 CpGs detected (Fig 2). Furthermore, seven PKOs had a very low density of CpGs with less than 10 CpGs 
identified in their PRs, which were LCK (0), FER (5), FAK (5), EPHB6 (8), DYRK1B (9), FRK(9) and FGR (9) (Fig 2). Two 
genes EPHB6 (28) and DYRK1B (44) had a high CpG density in their DFRs while the other five PKOs had low CpG density 
ranging from 4-13 in their DFRs (LCK, 4; FER, 13; FAK, 7; FRK, 3 and FGR, 10) (Fig 2). 
 
Figure 2.  Chimpanzee PK oncogene CpG density at the promoter and downstream flanking regions. In their PRs 69% of the chimpanzee PKOs have high 
CGD, and 31% have low CGD respectively. 
3.1.3. Mouse 
Figure 3 illustrates the CpG density and distribution in both PRs and DFRs of 61 mouse PKOs. Results showed that the 61 
mouse PK genes had an average of 38.6 CpGs in their PRs and 13.0 in their DFRs. 65% mouse PKOs had high CpG density 
and 35% had low density in their PRs respectively (Fig 3). Furthermore, three mouse PKOs exhibited to have over 100 CpGs 
in their PRs, with HIPK2 (137), IGF1R (133) and PKCE (116). These genes had 14, 21 and18 CpGs identified in their DFRs 
(Fig 3). Six mouse PKOs had less than 10 CpGs occurred in their PRs, which were ROS1 (5), AKT3 (5), FRK (7), FER (7), 
LTK (7) and MET (8). Three genes also had less than 10 CpGs occurred in their DFRs with AKT3 (5), FRK (3), and MET (7) 
while the other three genes: ROS1 (13), FER (15) and LTK (24) had more than 10 CpGs in their DFRs. 
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Figure 3.  Mouse PK oncogenes CpG density at the promoter and downstream flanking regions. In their PRs 66% of the mouse PKOs have high CGD and 
34% have low CGD respectively. 
3.1.4. Horse 
Figure 4 illustrates the CpG density and distribution in both PRs and DFRs of 61 horse PKOs. The 61 horse PKOs had an 
average density of 31.9 CpGs in their PRs and 17.9 in their DFRs, with 32 genes (52%) having high CpG density and 29 (48%) 
having low density in their PRs. However, none of the 61 horse PKOs had over 100 CpGs occurred in the PR. In contrast, six 
genes had only 10 CpGs detected in their PRs and seven had less than 10 CpGs, with CDC2 (6), HER4 (6), AKT3 (6), PBK 
(8), ABL2 (9), FLT4 (9) and COT(9). The CpG density in the DFRs of these genes in their PRs was alos low, but varied 
among them. 
The results clearly suggests that human PKOs have the highest density of CpGs occurred in their PRs, then the chimpanzee 
and mouse, and the horse the lowest. In addition, the CpG density in PRs is not associated with that in DFRs. 
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Figure 4.  Horse PK oncogene CpG density at the promoter region and downstream flanking regions. In their PRs 52% of the horse PKOs have high CGD, 
and 48% have low CGD respectively.  
3.2. Comparison of the CpG Distribution in Selected PKOs 
We compared the CpG distribution in the PR and DFR of selected PKOs of four species in order to estimate their 
evolutionary clue [19, 24]. Five PKOs were selected where substantial cross-species changes seemed to have taken place in 
their PRs and DFRs. For instance, the human AKT1 oncogene showed a higher number of CpGs in the PR than in any of the 
other three mammalian species (Fig 5, top group). Similarly, the CpG density in the PRs of FAK1 and HIPK2 has remained 
high in human and mouse but become low in chimpanzee and horse (Fig 5, 2nd and 3rd groups from top). However, The TRKA 
oncogenes appeared to have lost majority of CpGs in the PRs of human and mouse but remained high in the chimpanzee and 
horse (Fig 5, 2nd group from bottom). The LKB1 showed an apparent difference to the previous observations. The 
Chimpanzee LKB1 has a similarly high density of CpGs in both PR and DFR, making an apparent different pattern from 
those observed in human, mouse and horse PKOs which are comparatively low in both the PRs and DFRs (Fig 5, bottom 
group) 
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Figure 5.  Comparison of CpG density in the PR and DFR of 5 selected PKOs among four species. The labels on right hand side shows clusters of 
PKOs that have decreased / increased or shifted CpG density at the PRs. The human AKT1 shows a higher number of CpGs in the PR than in any of the other 
three mammalian species (top group). The CpG density in the PRs of FAK1 and HIPK2 has remained high in human and mouse but become low in 
chimpanzee and horse (2nd and 3rd groups from top). The TRKA appears to have lost majority of CpGs in the PRs of human and mouse but remained high in 
the chimpanzee and horse (2nd group from bottom). The LKB1 showed an apparent difference to the previous observations. The Chimpanzee LKB1 has a 
similarly high density of CpGs in both PR and DFR, making an apparent different pattern from those observed in human, mouse and horse PKOs which are 
comparatively low in both the PRs and DFRs (bottom group). 
3.3. The CpG-rich PKO Promoters and Their Expression Level in Tumour and Normal Tissues 
We next determined whether and how the CpG density in the PRs of the PKOs is associated with gene expression in 
tumour and normal tissues in both mouse and human because of no data available for Chimpanzee and horse. In human 
tumour tissues, the PKOs having more than 57 CpGs in their PRs did not show high levels of gene expression, suggesting that 
very high density of CpGs in the PR does not favour the PKO expression in tumour tissues (Fig 6a). Four peaks of the gene 
expression of the PKOs having a number of 12, 25, 36 and 46 CpGs were observed when the CpG density ranged from 10 to 
46, (Fig 6a). In human normal tissues, peaked gene expression was observed for the PKOs which have a number of 10, 15, 25, 
35, 46, 57, 68 and 94 CpGs in their PRs (Fig 6b). Three PKOs containing higher numbers of 57, 68 and 94 CpGs had much 
higher gene expression, especially the 57 CpGs-containing PKO showed extremely high gene expression (Fig 6b), in contrast, 
a very low expression of these PKOs was in tumour tissues (Fig 6a). Generally, the PKOs that are highly expressed in tumour 
tissues tend to have lower expression in normal tissues, associating with the CpG density in their PRs (Fig 6a, b). 
PKOs with the CpG density range of 20-76 in their PRs have much higher expression level in human than in mouse in 
tumour tissues (Fig 6a). But the PKOs of the two species have similar expression pattern and level in normal tissues, excepted 
for two genes (Fig 6b). The 57 CpGs-containing human PKO showed extremely high expression in normal tissues (Fig 6b), 
which was at least five times higher than the 57 CpGs-containing mouse PKO. In contrast, a 25 CpGs-containing human PKO 
had only one of third expression level, compared with the 25 CpGs-containing mouse PKO (Fig 6b). On an average, the PKO 
with high CpG density in the PRs have high expression in human than in mouse in both tumour and normal tissues (see table 
1), indicating that CpG density in the PRs associated with the PKO gene expression is specie-related. 
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Figure 6.  Comparison of the relationship between gene expression level and CpG density in protein kinase oncogene (PKO) in human and mouse. The 
graph (A) compares the expression level of PKO in tumour tissues whereas graph (B) contrast them in normal tissues. The vertical coordinates are expression 
levels and the horizontal coordinates are the densities of CpG dinucleotides in the promoter region. 
Table 1.  Comparison of expression levels in high and low CpG density at promoter region of PKO in tumour and normal tissues 
Oncogene 
Expression of PKO with high CpG 
density at the promoter region in 
tumour tissues 
Expression of PKO with high CpG 
density at the promoter region in 
normal tissues 
Expression of PKO with low CpG density at 
the promoter regions in tumour tissues 
Human Mouse Human Mouse Oncogene Human Mouse 
ABL2 14.03 0 7.05 1.32 ABL1 61.91 99.92 
AKT1 227.72 12.67 60.84 31.6 AKT3 0.91 0.8 
FAK1 60.63 18.98 67.59 18.1 DDR1 103.97 25.73 
FYN 21.25 4.28 44.79 34.3 FER 4.25 1.92 
PIM1 36.22 0.8 21.8 6.64 FRK 2.8 27.7 
SGK1 63.32 69.15 187.02 213.85 LCK 12.43 14.32 
SRM 44.67 7.86 44.67 17.95 MER 10.85 3.98 
VEGFR1 4.45 3.21 20.9 71.59 SRC 20.83 6.87 
Average 59.04 14.62 56.83 49.42 Average  27.24 22.66 
Highlighted numbers (red) are expression levels with statistical significance (P<0.02). 
4. Discussion 
Previous studies have reported that unmethylated CpGs in 
the PR served as a genomic footprint of replication origin [25, 
26]. In this report, we used human 61 PKOs as templates to 
compare the number of CpGs in the PR of the same genes in 
chimpanzee, horse and mouse genomes. As a result, the 
human PKOs had significantly higher density of CpGs 
occurred in their PRs, compared with the chimpanzee, mouse 
and horse PKOs. For instance, human focal adhesive kinase 
(FAK2) has more than 50 CpGs in its PR while the horse 
FAK2 only has 11 (see appendix 1). However, the human 
genome did not show that all the examined PKOs 
consistently have higher density of CpGs in their PRs than 
the other three species. A typical sample is that human TRKA 
has substantially decreased the CpGs density in the PR with 
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only 11 CpGs detected, compared with the horse TRKA gene 
that has 41 CpGs in its PR. The significant difference of the 
CpG density in the PKO PRs among the four compared 
species is probably due to their evolutionary impacts and 
changes. It is well documented that evolutionary tree of 
human genome is distinctly from that of the other 
mammalian species [27]. It has been reported that the 
evolutionary impacts and changes often target gene promoter 
region leading to a diverse arrangement of the nucleotides in 
this region [5, 28]. Molecularly, genetic transposition and 
recombination during the gene replication may play an 
important role in generating the high density of CpGs in both 
PRs and DFRs of human PKOs [29, 30]. The genetic 
transposition also contributed to the chimpanzee LKB1 gene 
to have very high density of CpGs in its DFR [31, 32]. Thus, 
it is likely that genetic transposition plays a key role in 
determining that chimpanzee LKB1 gene has 63 CpGs in PR 
and 133 CpGs in DFR while human LKB1 gene only 47 and 
11 in these two regions in the present study.  
In the present study, we observed first that human PKOs 
with a relatively high CpG density in the PRs are highly 
expressed in tumour tissues, consistent with previous studies 
that high CpGs density in the gene PR is associated with high 
gene expression [1-3]. This is probably due to the 
accumulations of methylated cytosines in the CpG-rich 
promoter regions that increase potentially the turnover rates 
of proto-oncogenes [33]. However, we observed further that 
human PKOs with a very high CpG density in the PRs 
exhibit very high expression in normal tissues. Thus, it 
appears that CpG occurrence and density in the PKO PRs 
may play a differential role in regulating their gene 
expression in human tumour and normal tissues. It has been 
reported that the occurrence and density of CpGs in the PRs 
of estrogen receptor genes and insulin-like growth factor 2 
gene are age-dependently varied in human tumours [34-37]. 
The variability of CpG density in the PR contributed in part 
to the high cancer risk associated with age over 70 in human 
to [38]. Thus, the occurrence and density of CpGs in the PR 
of PKOs and other oncogenes may be potentially served as 
an indicator of oncogene expression associated with the 
development of sporadic cancers in human.  
5. Conclusions 
The occurrence and density of CpGs in the PRs of the 61 
PKOs differ from one gene to another within individual 
species. On an average, human PKOs have much higher 
density of CpGs in the PRs than the other three species 
(chimpanzee, horse and mouse). The human PKO with 
relatively high density of CpGs (between 12-46 ) in the PRs 
are highly expressed in tumour tissues than in normal tissues. 
Differently, the human PKOs with extremely high density of 
CpGs (>57) in the PRs are highly expressed in normal tissues 
than in tumour tissues. The mechanism that CpGs density is 
linked to gene expression of the PKOs in human remains to 
be investigated. 
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